# Dihydroartemisinin (DHA)-Piperaquine for IPT to Prevent Malaria in Children in Burkina Faso

> **NCT00941785** · PHASE2,PHASE3 · COMPLETED · sponsor: **London School of Hygiene and Tropical Medicine** · enrollment: 1500 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** DHA-PQ
- **DRUG:** SP-AQ

## Key facts

- **NCT ID:** NCT00941785
- **Lead sponsor:** London School of Hygiene and Tropical Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 1500 (ACTUAL)
- **Last updated:** 2011-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00941785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00941785, "Dihydroartemisinin (DHA)-Piperaquine for IPT to Prevent Malaria in Children in Burkina Faso". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00941785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*